Schaeffer's 43rd Anniversary Stock Picks in 2024

Biotech Stock Blasts Higher After Upbeat Trial Data

2 analysts lifted their price targets after the update

Deputy Editor
Jun 28, 2022 at 10:27 AM
facebook X logo linkedin


Kezar Life Sciences Inc (NASDAQ:KZR) is skyrocketing today, up 84.1% at $10.55, after positive results from a mid-stage study of its kidney disorder drug, zetomipzomib. Following the data, Wells Fargo raised its price target to $17 from $13, while JonesTrading upped its price objective to $20 from $17. 

Today's pop has the equity recovering a good portion of its early-May bear gap, as well as removing it further from its mid-June lows. Still, the stock's 100-day moving average lingers just overhead as potential pressure. 

Analysts are wholeheartedly bullish on KZR, making today's bull notes more noteworthy. All five firms in coverage carry a "strong buy" rating, and the 12-month consensus price target of $19 is an 87% premium to current levels.  

Meanwhile, short interest has been building, up 19.7% during the most recent two-week reporting period. Now, the 4.30 million shares sold short account for 9.3% of the stock's available float. 

The equity's usually quiet options pits are bursting with activity today. So far, 7,591 calls and 3,231 puts have exchanged hands, which is 150 times what is typically seen at this point. Most popular is the July 12.50 call, followed by the October 21 call, with positions being opened at the latter.

 

A.I.’s Dirty Little Secret: The Real Power Behind The AI. Boom ✨

Anyone who’s seen the The Matrix movies knows that A.I. needs power.  Lots and lots of power.

If you’ve seen the movie, you also know the grizzly results of the ensuing battle for that power.

Now, Wall Street’s battle for A.I. power won’t go to such extremes. Hopefully?

A.I. needs more power and that means more opportunities for stock traders in the know.

Download your free copy of “The A.I. Revolution: 4 Stocks to Buy Now”!